Alumis Inc. (ALMS) Stock Price & How to Invest

Alumis Inc. (Nasdaq: ALMS) is a clinical-stage biopharmaceutical company developing oral, precision-designed therapies for immune-mediated diseases. Its lead candidate, envudeucitinib (formerly ESK-001), is an allosteric TYK2 inhibitor that posted positive Phase 3 ONWARD1 and ONWARD2 topline results in moderate-to-severe plaque psoriasis (roughly 65% PASI 90 and over 40% PASI 100 at week 24), with an NDA submission planned for the second half of 2026. The pipeline also includes envudeucitinib in a Phase 2b lupus (SLE) trial, A-005 (a CNS-penetrant TYK2 inhibitor aimed at multiple sclerosis), and lonigutamab (an anti-IGF-1R antibody for thyroid eye disease) that came in through the 2025 merger with ACELYRIN.

Because Alumis has no approved products, it generates essentially no product revenue and runs at a large operating loss funded by cash on hand. The all-stock ACELYRIN merger and a January 2026 equity offering (roughly $345 million gross at $17.00 per share) shored up the balance sheet, giving the combined company runway to advance its programs through multiple planned data readouts. The investment picture is therefore binary in character: success at the FDA and in a competitive TYK2 market could re-rate the stock, while a clinical or regulatory setback could sharply reduce it.

As a clinical-stage company, Alumis has essentially no product revenue and burns cash on research and development, so its shares are highly sensitive to trial and regulatory outcomes. FDA approval is not guaranteed, and even after approval the TYK2 space is competitive, led by Bristol Myers Squibb's already-marketed Sotyktu (deucravacitinib) and other entrants in development. Future equity raises could dilute existing holders, and integration of the ACELYRIN merger adds execution risk. Any single clinical, safety, or commercial disappointment could move the stock sharply, which is characteristic of pre-revenue biotech.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Alumis Inc.'s investor relations page or your broker.

• Product revenue (TTM): ~$0 (clinical-stage, no approved products)
• Market cap: ~$2.9B
• Pro forma cash (post-merger): ~$737M as of Dec 31, 2024
• January 2026 equity raise: ~$345M gross ($17.00/share)
• Cash runway: into 2027
• Lead asset milestone: psoriasis NDA planned 2H 2026

Alumis cannot be valued on earnings because it has no meaningful revenue and operates at a loss, so the market prices it on the probability-weighted value of its pipeline, chiefly envudeucitinib. The reported market cap reflects investor expectations for approval and launch rather than current cash flow. Balance-sheet strength from the merger and the 2026 raise matters here because runway determines how many catalysts the company can reach before needing more capital.

There are three common ways to get ALMS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so ALMS sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where ALMS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Alumis is a pre-revenue clinical-stage story with strong Phase 3 psoriasis data and a well-funded balance sheet, but the outcome depends on FDA approval and commercial uptake, which makes it a high-variance holding.

Whether ALMS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is ALMS a buy?, and where the stock could go from here in the ALMS stock forecast.

For income investors, whether ALMS pays a dividend and how the payout looks is covered in does ALMS pay a dividend?